Sign In to Follow Application
View All Documents & Correspondence

Indole And Indazole Derivatives Having A Cell , Tissue And Organ Preserving Effect

Abstract: The present invention relates to a composition for preserving cells, tissues and organs, comprising as an active ingredient indole and indazole compounds of formula (1), or a pharmaceutically acceptable salt or isomer thereof, which are effective for preventing injury of organs, isolated cell systems or tissues caused by cold storage, transplant operation or post-transplantation reperfusion; a preservation method; and a preparation method of the composition.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
29 June 2010
Publication Number
51/2010
Publication Type
INA
Invention Field
CHEMICAL
Status
Email
Parent Application

Applicants

LG LIFE SCIENCES LTD.
LG TWIN TOWER, EAST TOWER, 20, YOIDO-DONG, YOUNGDEUNGPO-GU, SEOUL 150-010.

Inventors

1. KIM, SOON HA
R&D PARK, LG LIFE SCIENCES LTD., 104-1, MOONGI-DONG, YUSEONG-GU, DAEJEON 305-380.
2. KIM, HYOUNG JIN
R&D PARK, LG SCIENCES LTD., 104-1, MOONGI-DONG, YUSEONG-GU, DAEJEON-305-380.
3. CHUNG, CHUL, WOONG
R&D PARK, LG LIFE SCIENCES LTD., 104-1, MOONGIDONG, YUSEONG-GU, DAEJEON 305-380.
4. PARK, HEUI SUL
R&D PARK, LG LIFE SCIENCES LTD., 104-1, MOONGIDONG, YUSEONG-GU, DAEJEON 305-380.
5. KWAK, HYO SHIN
R&D PARK, LG LIFE SCIENCES LTD., 104-1, MOONGIDONG, YUSEONG-GU, DAEJEON 305-380.
6. KIM, SUNG HO
R&D PARK, LG LIFE SCIENCES LTD., 104-1, MOONGIDONG, YUSEONG-GU, DAEJEON 305-380.
7. PARK, JIN GU
R&D PARK, LG LIFE SCIENCES LTD., 104-1, MOONGIDONG, YUSEONG-GU, DAEJEON 305-380.

Specification

CLAIMS

[Claim 1]

A composition for preserving cells and organs comprising as an effective ingredient, a compound of the following formula (1) or a pharmaceutically acceptable salt or isomer thereof:
wherein
X represents C or N,
n is 0 or 1, and n is 1 when X is C and n is 0 when X is N,
A represents a direct bond, C3-C8-cycloalkyl, phenyl, or 5~6-membered heteroaryl or heterocycle, each of which includes 1~3 heteroatoms selected from N, O and S atoms,
R1 represents hydrogen, -C(O)-B-X'-R7 or -(CR5R6)m,-B-X'-R7,
m is an integer of 0 to 4,
each of R5 and R6 independently represents hydrogen or C1-C5-alkyl,
B represents a direct bond, C3-C8-cycloalkyl optionally containing oxo, or 3-10-membered heterocycle or heteroaryl, each of which includes 1-3 heteroatoms selected from O, S and N atoms,
X' represents a direct bond, -C(O)-, -SO2-, -CO2- or -C(O)NR5-,
R7 represents hydrogen, C1-C6-alkyl, halogeno-C1-C6-alkyl, halogen, (CR5R6)m-phenyl, (CR5R6)m,-hydroxy or (CR5R6)m,-heterocycle where the heterocycle optionally contains oxo and is a 3~10-membered ring including 1-3 heteroatoms selected from N, O and S atoms,
R2 represents -(CR5R6)m-D-X"-R8,
D represents a direct bond or a 3~10-membered heterocycle or heteroaryl, each of which optionally contains oxo and is optionally fused, and includes 1-4 heteroatoms selected from N, O and S atoms,
X" represents a direct bond, -C(O)-, -C(O)O-, -NR5C(O)-, -C(O)NR5- or -O-,
R8 represents hydrogen, halogen, C1-C6-alkyl, halogeno-C1-C6-alkyl, tri(C1-C6-alkyl)silane or hydroxy-C1-C6-alkyl,
R3 represents hydrogen, halogen, cyano, nitro, aryl-R9 or (CR5R6)m-D-R9,
R9 represents hydrogen, halogen, C1-C6-alkyl, cyano, nitro or C1-C6-alkoxy,
R4 represents -(CR5R6)m,-Y-D-R10,
Y represents a direct bond, -C(O)O- or -O-, and
R10 represents hydrogen, nitro, halogen, C1-C6-alkyl, carboxy-C1-C6-alkyl, aryl or -C(O)O-R5,
wherein each of said alkyl, alkoxy, aryl, cycloalkyl, heterocycle and heteroaryl is optionally substituted with one or more substituents selected from the group consisting of hydroxy, halogen, nitrile, amino, C1-C6-alkylamino, di(C1-C6-alkyl)amino, C1-C6-alkyl, halogeno-C1-C6-alkyl, C1-C6-alkylsulfonyI, aryl-C1-C6-alkoxy and oxo.

[Claim 2]
The composition according to claim 1, wherein X represents C or N, n is 0 or 1, and n is 1 when X is C and n is 0 when X is N,
A represents a direct bond, phenyl, or 5~6-membered heteroaryl or heterocycle, each of which includes 1-3 heteroatoms selected from N, O and S atoms,
R1 represents hydrogen, -C(0)-B-X'-R7 or -(CR5R6)n,-B-X'-R7,
m is an integer of 0 to 2,
each of R5 and R6 independently represents hydrogen or C1-C5-alkyl,
B represents a direct bond, C4-C7-cycloalkyl optionally containing oxo, or 4~8-membered heterocycle or heteroaryl, each of which includes 1-3 heteroatoms selected from 0, S and N atoms,
X' represents a direct bond, -C(O)-, -SO2-, -CO2- or -C(O)NH-,
R7 represents hydrogen, C1-C6-alkyl, halogeno-C1-C6-alkyl, halogen, (CR5R6)m-phenyl, (CR5R6)m-hydroxy or (CR5R6)m-heterocycle where the heterocycle optionally contains 0x0 and is a 4~8-membered ring including 1~3 heteroatoms selected from N, O and S atoms,
R2 represents -(CR5R6)m-D-X"-R8,
D represents a direct bond or a 4~8-membered heterocycle or heteroaryl, each of which optionally contains 0x0 and is optionally fused, and includes 1-4 heteroatoms selected from N, O and S atoms.
X"represents -C(O)-, -C(O)O-, -NR5C(O)-, -C(O)NR5- or -O-,
R8 represents hydrogen, halogen, C1-C6-alkyl, halogeno-C1-C6-alkyl, tri(C]-C6-alkyl)silane or hydroxy-C1-C6-alkyl,
R3 represents hydrogen, halogen, cyano, nitro, aryl-R9 or (CR5R6)m-D-R9,
R9 represents hydrogen, halogen, C1-C6-alkyl, cyano, nitro or C1-C6-alkoxy,
R4 represents -(CR5R6)m,-Y-D-R10,
Y represents a direct bond, -C(O)O- or -O-, and
R10 represents hydrogen, nitro, halogen, C1-C6-alkyl, carboxy-C1-C6-alkyl, aryl or -C(O)O-R5.

[Claim 3]
The composition according to claim 2, wherein the compound of the formula (1) has an indazole structure of the following formula (la) or an indazole structure of the following formula (lb):

[Claim 4]
The composition according to claim 2, wherein A is selected from the group consisting of phenyl, pyridine, 1,4-pyrazine, 4,5-dihydro-thiazole, thiazole, 4,5-dihydrooxazole, [l,2,4]oxadiazoIe and [l,3,4]oxadiazole.

[Claim 5]
The composition according to claim 2, wherein Rl represents -C(O)-B-X'-R7 or -(CHR5)m-B-X'-R7 where m is an integer of 0 to 2; R5 represents C1-C3-alkyl; B represents a direct bond, C5-C6-cycloalkyl optionally containing oxo, or 5~6-membered heterocycle or heteroaryl, each of which includes 1~3 heteroatoms selected from O, S and N atoms; X' represents a direct bond, -C(O)-, -SO2-, -CO2- or -C(0)NH-; and R7 represents hydrogen, C1-C3-alkyl, halogeno-C1-C3-alkyl, halogen, (CH2)m-phenyl, (CH2)m-hydroxy or (CH2)m-heterocycle where the heterocycle optionally contains 0x0 and is a 5~6-membered ring including 1-3 heteroatoms selected from N, O and S atoms.

[Claim 6]
The composition according to claim 5, wherein B is selected from the group consisting of cyclopentyl, cyclohexyl, piperidine, tetrahydropyran, oxocyclohexyl, pyrrolidine difluorocyclohexyl and tetrahydrofuran.

[Claim 7]
The composition according to claim 5, wherein R7 is selected from the group consisting of hydrogen, methyl, ethyl, isopropyl, benzyl, hydroxymethyl, (morpholine-4-yl)-ethyl, tetrahydrofuran, 2,2,2-trifluoroethyl, hydroxyethyl, 1,1-dioxothiomorpholine, tetrahydropyran, (tetrahydropyran-4-yl)-methyl and trifluoromethyl.

[Claim 8]
The composition according to claim 2, wherein D represents a direct bond, or is selected from the group consisting of piperazine, pyrrolidine, morpholine, 1,1-dioxothiomorpholine and oxopiperazine.

[Claim 9]
The composition according to claim 2, wherein R8 is selected from the group consisting of hydrogen, ethyl, hydroxymethyl, methyl and fluorine.

[Claim 10]
The composition according to claim 2, wherein R3 represents hydrogen; halogen; phenyl optionally substituted with alkoxy; or 6-membered heterocyclylmethyl including 1~3 heteroatoms selected from N, S and O atoms as ring members and optionally containing oxo.

[Claim 11]
The composition according to claim 10, wherein R3 is selected from the group consisting of hydrogen, bromine, phenyl, methoxy-phenyl, morpholine-4-yl-methyl, oxopiperazine-4-yl-methyl and 1, l-dioxo-thiomorpholine-4-yl-methyl.

[Claim 12]
The composition according to claim 2, wherein R4 represents -(CH2)m-Y-D-R10 where m is an integer of 0 to 2; Y represents a direct bond, -C(O)O- or -O-; D represents pyridine or 5~6-membered heterocycle including 1~3 heteroatoms selected from N, S and O atoms and optionally containing oxo; and RIO represents hydrogen, halogen, C1-C3-alkyl, -(CH9)-CO2H, aryl or -C(O)O-R5.

[Claim 13]
The composition according to claim 12, wherein D is selected from the group consisting of 1,1-dioxo-thio-morpholine, oxopiperazine, pyridine, morpholine and 4,5-dihydro-thiazole.

[Claim 14]
The composition according to claim 12, wherein R10 is selected from the group consisting of hydrogen, fluorine, chlorine, bromine, methyl, ethyl and -(CH2)-CO2H.

[Claim 15]
The composition according to claim 2, wherein the compound is selected from the group consisting of:
cyclopentyl- [2-(4,5-dihydro-1,3-thiazole-2-yl)-1 H-indole-7-yl]-amine;
[2-(4,5-dihydro-thiazole-2-yl)-lH-indole-7-yl]-(4-methyl-cyclohexyI)-amine;
[2-(4,5-dihydro-thiazole-2-yl)-lH-indole-7-yl]-piperidine-4-yl-amine;
2-5-[7-(tetrahydro-pyran-4-ylamino)-lH-indole-2-yl]-[l,2,4]oxadiazole-3-yl}-ethanol;
[(R)-2-(7-cycIopentylamino-lH-indole-2-yl)-4,5-dihydro-l,3-thiazole-4-yl]-methanol; cyclopentyl-[2-((R)-4-pyrrolidine-l-ylmethyl-4,5-dihydro-thiazole-2-yl)-lH-indole-7-yl] -amine;
{(R)-2-[7-(tetrahydro-pyran-4-ylamino)-lH-indole-2-yl]-4,5-dihydro-thiazole-4-yl}-methanol;
[(R)-2-(7-cycIopentyIamino-5-fluoro-lH-indole-2-yI)-4,5-dihydro-thiazole-4-yI]-methanol;
{(R)-2-[5-fluoro-7-(tetrahydro-pyran-4-ylamino)-lH-indole-2-yl]-4,5-dihydro-thiazole-4 --y1}-methanol;
{(R)-2-[5-(pyridine-3-yloxy)-7-(tetrahydro-pyran-4-ylamino)-lH-indole-2-yl]-4,5-dihyd ro-thiazole-4-yl}-methanol;
[(R)-2-(5-chloro-7-cyclopentylamino-lH-indoIe-2-yl)-4,5-dihydro-thiazole-4-yl]-acetic acid;
[(R)-2-(5-chloro-7-cyclopentylamino-lH-indole-2-yl)-4,5-dihydro-thiazole-4-yl]-acetic acid ethyl ester;
2-{(R)-2-[5-chloro-7-(tetrahydro-pyran-4-ylamino)-lH-indole-2-yl]-4,5-dihydro-thiazol e-4-yl}-ethanol;
l-[4-(2-{(R)-2-[5-chloro-7-(tetrahydro-pyran-4-ylamino)-lH-indole-2-yl]-4,5-dihydro-th iazole-4-yl} -ethyl)-piperazine-1-y1] -2-hydroxy-ethanone;
1-(2-{(R)-2-[5-chloro-7-(tetrahydro-pyran-4-ylamino)-lH-indole-2-yl]-4,5-dihydro-thiaz ole-4-yI}-ethyl)-pyrrolidine-3-ol;
[(R)-2-(5-bromo-7-cyclopentylamino-lH-indole-2-yl)-4,5-dihydro-thiazole-4-yi]-acetic acid;
[(R)-2-(7-cyclopentylamino-5-ethoxy-lH-indole-2-yl)-4,5-dihydro-thiazole-4-yl]-acetic acid;
[(R)-2-(7-cyclopentylamino-5-ethoxy-lH-indole-2-yl)-4,5-dihydro-thiazole-4-yl]-acetic acid;
[2-(7-cyclopentylamino-5-phenoxy-lH-indole-2-yl)-4,5-dihydro-thiazole-4-yl]-acetic acid;
[(R)-2-(7-cyclopentylamino-5-phenoxy-lH-indole-2-yl)-4,5-dihydro-thiazole-4-yl]-acetic acid;
[(S)-2-(7-cyclopentylamino-5-phenoxy-lH-indole-2-yl)-4,5-dihydro-thiazole-4-yl]-acetic c acid;
3-[(R)-2-(5-chloro-7-cyclopentylamino-lH-indole-2-yl)-4,5-dihydro-thiazole-4-yl]-propi onic acid ethyl ester;
3- [(R)-2-(5-chloro-7-cyclopentylamino-1 H-indole-2-yl)-4,5-dihydro-thiazole-4-yl] -propi onic acid;
cyclopentyl-(2-pyridine-2-yl-lH-indole-7-yl)-amine;
cyclopentyl-(2-pyrazine-2-yl-lH-indole-7-yl)amine;
(2-pyrazine-2-yl-lH-indole-7-yl)-(tetrahydropyran-4-yl)-amine;
cyclopentyl-(2-thiazole-2-yl-1 H-indole-7-yl)-amine;
2-(7-cyclopentylamino-5-methyl-lH-indole-2-yl)-thiazole-4-carboxylic acid ethyl ester;
2-(7-cyclopentylamino-5-methyl-lH-indole-2-yl)-thiazole-4-carboxylic acid;
[2-(7-cyclopentylamino-5-methyl-lH-indole-2-yl)-thiazole-4-yl]-methanol;
[2-(7-cyclopentylamino-5-methyl-lH-indole-2-yl)-thiazole-5-yl]-methanol;
cyclopentyl-(5-methyl-2-[l,3,4]oxadiazole-2-yl-lH-indole-7-yl)-amine;
cyclopentyl-(5-methyl-2-pyridine-2-yl-lH-indole-7-yl)-amine;
(5-methyl-2-pyridine-2-yl-lH-indole-7-yl)-(tetrahydro-pyran-4-yl)-amine;
cyclohexyl-(5-methyl-2-pyridine-2-yl-lH-indole-7-yl)-amine;
l-[4-(5-methyl-2-pyridine-2-yl-lH-indole-7-ylamino)-piperidine-1-y1]-ethanone;
(l-methyl-piperidine-4-yl)-(5-methyl-2-pyridine-2-yl-lH-indole-7-yl)-amine;
4-(5-methyl-2-pyridine-2-yl-lH-indole-7-ylamino)-cyclohexanone;
(l-benzyl-pyrrolidine-3-yl)-(5-methyl-2-pyridine-2-yl-lH-indole-7-yl)-amine;
cyclopentylmethyl-(5-methyl-2-pyridine-2-yl-lH-indole-7-yl)-amine;
N-(5-methyl-2-pyridine-2-yl-lH-indole-7-yI)-benzamide;
cyclopentyl-(5-methyl-2-pyrazine-2-yl-lH-indole-7-yl)-amine;
cyclopentyl-(5-ethoxy-2-pyridine-2-yl-lH-indole-7-yl)-amine;
cyclopentyl-(5-phenoxy-2-pyridine-2-yl-1 H-indole-7-yl)-amine;
cyclopentyl-(3,5-dimethyl-2-phenyl-lH-indole-7-yl)-amine;
cyclopentyl-(5-methyl-2-phenyl-lH-indole-7-yl)-amine;
(2-cyclohexyl-5-methyl-lH-indole-7-yl)-cyclopentyl-amine;
cyclopentyl-[5-methyl-2-(6-methyl-pyridine-2-yl)-lH-indole-7-yl]-amine;
(5-methyl-2-phenyl-lH-indoIe-7-yI)-(tetrahydro-pyran-4-yl)-amine;
(5-methyI-2-phenyl-lH-indoIe-7-yl)-(l-methyl-piperidine-4-yl)-amine;
l-[4-(5-methyI-2-phenyl-lH-indole-7-ylamino)-piperidine-1-y1]-ethanone;
(5-methyl-2-phenyl-lH-indole-7-yl)-piperidine-4-yl-amine hydrochloride;
2-hydroxy-l-[4-(5-methyl-2-phenyl-lH-indole-7-ylamino)-piperidine-1-y1]-ethanone;
(1 -methanesulfonyl-piperidine-4-yl)-(5 -methyl-2-phenyl-1 H-indole-7-y l)-amine;
4-(5-methyl-2-phenyI- lH-indole-7-ylamino)-cyclohexanecarboxylic acid;
4-(5-methyl-2-phenyl-lH-indole-7-ylamino)-cyclohexanecarboxylic acid
(2-morpholine-4-yl-ethyl)-amide;
cyclopentylmethyl-(5-methyl-2-phenyl-lH-indole-7-yl)-amine;
(5-methyl-2-phenyl-lH-indole-7-yl)-(tetrahydro-pyran-4-ylmethyl)-amine;
(5-chloro-2-phenyl-lH-indole-7-yl)-cyclopentyl-amine;
(5-chloro-2-phenyl-lH-indoIe-7-yl)-(tetrahydro-pyran-4-yl)-amine;
(5-chloro-2-phenyl-lH-indole-7-yl)-(l-methyl-piperidine-4-yl)-amine;
(5-chloro-2-phenyl-lH-indole-7-yl)-cyclohexyl-amine;
(1-benz:y1-pyrrolidine-3-yl)-(5-chloro-2-phenyl-lH-indole-7-yl)-amine;
4-(5-chloro-7-cyclopentylamino-lH-indole-2-yl)-benzoic acid methyl ester; 4-(5-chloro-7-cyclopentylamino- lH-indole-2-yl)-benzoic acid; [4-(5-chloro-7-cyclopentylamino-lH-indole-2-yl)-phenyl]-methanol; 4-(7-cyclopentylamino-5-methyl-lH-indole-2-yl)-benzoic acid methyl ester; 2-(5-chloro-7-cyclopentylamino-lH-indole-2-yl)-benzoic acid methyl ester; 2-(5-chloro-7-cyclopentylamino-lH-indole-2-yl)-benzoic acid; [2-(5-chloro-7-cyclopentylamino-lH-indole-2-yl)-phenyl]-methanol; 7-cyclopentylamino-2-phenyl-lH-indole-5-carboxylic acid ethylester; 7-cyclopentylamino-2-phenyl- lH-indole-5-carboxylic acid; (7-cyclopentylamino-2-phenyl-lH-indole-5-yl)-methanol; (7-cyclopentylamino-2-phenyl-lH-indole-5-yl)-acetic acid ethyl ester; (7-cyclopentylamino-2-phenyl-lH-indole-5-yl)-acetic acid;
2-[(4S)-2-[5-methyl-7-(oxane-4-ylmethylamino)-lH-indole-2-yI]-4,5-dihydro-l,3-thiazol e-4-yl]acetic acid;
2-[(4S)-2-[5-chloro-7-(oxane-4-ylmethylamino)-lH-indole-2-yl]-4,5-dihydro-l,3-thiazol e-4-yl]acetic acid;
2-[(4S)-2-[7-[(4,4-difluorocyclohexyl)amino]-5-methyl-lH-indole-2-yl]-4,5-dihydro-l,3-thiazole-4-yl]acetic acid;
2-[(4S)-2-[7-(oxane-4-ylamino)-5-phenoxy-lH-indole-2-yl]-4,5-dihydro-l,3-thiazole-4-y l]acetic acid;
2-[(4R)-2-[7-(oxane-4-ylamino)-5-phenoxy-lH-indole-2-yl]-4,5-dihydro-l,3-thiazole-4-y l]acetic acid;
2-[(4R)-2-[7-(oxane-4-ylmethylamino)-5-phenoxy-lH-indole-2-yl]-4,5-dihydro-l,3-thiaz ole-4-yl]acetic acid;
2-[(4S)-2-[7-(cyclopentylamino)-lH-indole-2-yl]-4,5-dihydro-l,3-thiazole-4-yl]acetic acid;
2-[(4S)-2-[7-[(l-acetylpyrrolidine-3-yl)amino]-5-methyl-lH-indole-2-yl]-4,5-dihydro-l,3 -thiazole-4-yl]acetic acid;
2-[(4S)-2-[7-(oxane-4-yImethylamino)-lH-indole-2-yl]-4,5-dihydro-l,3-thiazole-4-yl]ace tic acid;
2-[(4S)-2-[7-(oxane-4-ylamino)-lH-indole-2-yl]-4,5-dihydro-l,3-thiazole-4-yl]acetic acid;
2-[(4S)-2-[7-(oxane-2-ylmethylamino)-lH-indole-2-yl]-4,5-dihydro-l,3-thiazole-4-yl]ace tic acid;
2-[(4S)-2-[5-methyl-7-[[l-(3,3,3-trifluoropropanoyl)piperidine-4-yl]amino]-lH-indole-2-yl]-4,5-dihydro- l,3-thiazole-4-yl]acetic acid;
2-[(4R)-2-[7-(cyclopentylamino)-5-methyl-lH-indole-2-yI]-4,5-dihydro-l,3-thiazole-4-yl ]acetic acid;
2- [(4R)-2- [5-methyl-7-(oxane-4-ylmethylamino)-1 H-indole-2-yl] -4,5 -dihy dro-1,3-thiazoI e-4-yl]acetic acid;
4-[2-[(4S)-2-[5-methyl-7-(oxane-4-ylmethylamino)-lH-indole-2-yl]-4,5-dihydro-l,3-thia zole-4-yl]ethyl]piperazine-2-one;
2-[(4S)-4-[2-(l,l-dioxo-l,4-thiazinane-4-yl)ethyl]-4,5-dihydro-l,3-thiazole-2-yl]-5-meth yl-N-(oxane-4-ylmethyl)-1 H-indole-7-yl-amine;
N-(4,4-difluorocyclohexyl)-5-methyl-2-[(4S)-4-(2-morpholine-4-ylethyl)-
4,5-dihydro-l,3-thiazole-2-yl]-lH-indole-7-yl-amine;
4-[2-[(4S)-2-[7-[(4,4-difluorocyclohexyl)amino]-5-methyl-lH-indole-2-yl]-4,5-clihydro-l ,3-thiazole-4-yl]ethyl]piperazine-2-one;
4-[2-[(4S)-2-[7-(oxane-4-ylmethylamino)-5-phenoxy-lH-indole-2-yl]-4,5-dihydro-l,3-thi azole-4-yl]ethyl]piperazine-2-one;
2-[(4S)-4-(2-morpholine-4-ylethyl)-4,5-dihydro-l,3-thiazole-2-yl]-N-(oxane-4-ylmethyl) -5-phenoxy-lH-indole-7-amine;
5-methyl-2-[(4S)-4-(2-morpholine-4-ylethyl)-4,5-dihydro-l,3-thiazole-2-yl]-N-(oxane-4-ylmethyl)- lH-indole-7-amine;
l-[2-[(4S)-2-[5-methyl-7-(oxane-4-ylmethylamino)-lH-indole-2-yl]-4,5-dihydro-l,3-thia zole-4-yI]ethyl]piperidine-4-carboxyamide;
[(2R)-l-[2-[(4S)-2-[5-methyl-7-(oxane-4-ylmethylamino)-lH-indoIe-2-yl]-4,5-dihydro-l, 3-thiazole-4-yl]ethyl]pyrrolidine-2-yl]methanol;
(2S)-l-[2-[(4S)-2-[5-methyl-7-(oxane-4-ylmethylamino)-lH-indole-2-yl]-4,5-dihydro-l,3 -thiazole-4-yl]ethyl]pyrrolidine-2-carboxyamide;
4-[2-[(4R)-2-[7-(cyclopentylamino)-5-methyl-lH-indole-2-yl]-4,5-dihydro-l,3-thiazole-4 -yl]ethyl]piperazine-2-one;
2-[(4S)-2-[7-(cyclopentylamino)-5-methyl-lH-indole-2-yl]-4,5-dihydro-l,3-oxazole-4-yl Jacetic acid;
{(S)-2-[5-methyl-7-(tetrahydropyran-4-ylamino)-lH-indole-2-yl]-4,5-dihydro-oxazole-4-yl}-acetic acid;
2-[(4S)-2-[5-methyl-7-(tetrahydropyran-4-ylamino)-lH-indole-2-yl]-4,5-dihydro-l,3-oxa zole-4-yl]ethanol;
{5-methyl-2-[(S)-4-(2-morpholine-4-yl-ethyl)-4,5-dihydro-l,3-oxazole-2-yl]-lH-indole-7 -yl} -(tetrahydro-pyran-4-yl)amine
4-[(5-chloro-2-phenyl-lH-indole-7-yl)amino]-N-ethylpiperidine-l-carboxyamide;
[4-[(5-chloro-2-phenyi-lH-indole-7-yl)amino]piperidine-1-y1]-(oxoIan-3-yI)methanone; 2-[7-(oxane-4-ylamino)-2-phenyl-lH-indole-5-yl]acetic acid;
2-[7-(cyclopentylmethylamino)-2-phenyl-lH-indole-5-yl]aceticacid;
5-fluoro-N-(l-methylpiperidine-4-yl)-2-pheny1-1H-indole-7-amine;
2-[4-[(5-fluoro-2-phenyl-lH-indole-7-y1)amino]piperidine-1-y1]ethanone;
5-fluoro-N-[l-(oxane-4-yl)piperidine-4-yl]-2-phenyl-lH-indole-7-amine;
N-[l-(l,l-dioxan-4-yi)piperidine-4-yl]-5-fluoro-2-phenyI-lH-indoIe-7-amine;
N-(oxane-4-yl)-5-phenoxy-2-phenyl-lH-indole-7-amine;
methyl 2-[(5-fluoro-2-phenyl-lH-indoIe-7-yl)amino]acetate;
2-[(5-fluoro-2-phenyl-lH-indole-7-yl)amino]acetic acid;
methyl 2-[(5-chloro-2-phenyl-lH-indole-7-yl)amino]propanoate;
2-[(5-chloro-2-phenyl-lH-indole-7-yl)amino]propanoic acid; 2-[(5-phenoxy-2-phenyl-lH-indole-7-yl)amino]acetic acid; 2-[(5-phenoxy-2-phenyl- lH-indole-7-yl)amino]propanoic acid;
2-[(4S)-2-[7-(oxane-4-ylmethylamino)-2-phenyl-lH-indole-5-yl]-4,5-dihydro-l,3-thiazol e-4-yl]acetic acid;
2-[(4S)-2-[7-(cyclopentylamino)-2-phenyl-lH-indole-5-yl]-4,5-dihydro-l,3-thiazole-4-yi ]acetic acid;
methyl 2-[4-[5-chloro-7-(oxane-4-ylamino)-lH-indole-2-yl]phenyl]acetate;
methyl 2-[4-[5-chIoro-7-(oxane-4-yImethyIamino)-lH-indoIe-2-yI]phenyl]acetate;
2-[4-[5-chloro-7-(oxane-4-ylamino)-lH-indole-2-yl]phenyl]acetic acid;
5-[( 1,1 -dioxo-1,4-thiazinane-4-yl)methyl] -N-(oxane-4-yl)-2-pheny 1- lH-indole-7-amine;
5-[(l,l-dioxo-l,4-thiazinane-4-yl)methyl]-N-(oxane-4-ylmethyl)-2-phenyl-lH-indole-7-a mine;
4-[[7-(oxane-4-ylamino)-2-phenyl-lH-indole-5-yl]methyl]piperazine-2-one; 5- [(1,1-dioxo-1,4-thiazinane-4-yl)methyl] -2-phenyl-N-piperidine-4-y 1-1 H-indoIe-7-amin e;
[4-[[5-[(l,l-dioxo-l,4-thiazinane-4-yl)methyl]-2-phenyl-lH-indole-7-yl]amino]piperidin e-1-yI]-(oxolan-3-yl)methanone;
N-[4-[5-[(l,l-dioxo-l,4-thiazinane-4-yl)methyl]-7-(oxane-4-ylamino)-lH-indole-2-yl]ph enyljacetamide;
N- [4- [7-(dicyclopentylamino)-5- [(1,1 -dioxo-1,4-thiazinane-4-yl)methyl] -1 H-indoIe-2-y I] phenyl]acetamide;
N- [4- [5- [(1,1 -dioxo-1,4-thiazinane-4-yl)methyl] -7-(oxane-4-ylmethylamino)- IH-indole-2-yl]phenyl]acetamide;
N-cyclopentyl-5-[(14-dioxo-l,4-thiazinane-4-yl)methyl]-2-(4-methoxyphenyl)-1H-indol e-7-amine;
5-[(l,l-dioxo-l,4-thiazinane-4-yl)methyl]-2-(4-methoxyphenyl)-N-(oxane-4-yl)-1H-indo le-7-amine;
5-[(l,l-dioxo-l,4-thiazinane-4-yl)methyl]-N-(3-methoxybutyl)-2-phenyl-lH-indole-7-amine;
5-[(l,l-dioxo-l,4-thiazinane-4-yl)methyl]-2-(3-fluorophenyl)-N-(oxane-4-yl)-lH-indole-7-amine;
N-cyclopentyl-5-[(l,l-dioxo-l,4-thiazinane-4-yl)methyl]-2-(3-fluorophenyl)-lH-indole-7 -amine;
3-bromo-5-[(l,l-dioxo-l,4-thiazinane-4-yl)methyl]-N-(oxane-4-yl)-2-phenyl-lH-indole-7-araine;
3-bromo-5-(morpholine-4-ylmethyl)-N-(oxane-4-yl)-2-phenyl-lH-indole-7-amine;
3-bromo-N-cyclopentyI-5-[(1,1-dioxo-l,4-thiazinane-4-yl)methyl]-2-phenyl-lH-indole-7 -amine;
3-bromo-5-[(l,l-dioxo-l,4-thiazinane-4-yl)methyl]-N-(oxane-4-yl).2-phenyl-lH-indole-7-amine;
5-chloro-N-(oxane-4-yl)-3-phenyl-lH-indole-7-amine;
5-chloro-N-cyclopentyl-3-phenyl-lH-indole-7-amine;
5-chloro-N-(oxane-4-ylmethyl)-3-phenyl-lH-indole-7-amine;
5-[(l,l-dioxo-l,4-thiazinane-4-yl)methyl]-N-(oxane-4-yl)-3-phenyl-2-trimethylsilyl-lH-i ndole-7-amine;
4-[[5-chloro-7-(cyclopentylamino)-2-phenyl-lH-indole-3-yl]methy1]piperazine-2-one; 4-[[5-chloro-7-(oxane-4-ylamino)-2-phenyI-lH-indole-3-yl]methyl]piperazine-2-one;
4-[[5-chloro-7-(oxane-4-ylmethylamino)-2-phenyl-lH-indole-3-yl]methyl]piperazine-2-one;
N-cyclopentyl-3-(4-methoxyphenyl)-lH-indazol-7-amine; 3-(4-methoxyphenyl)-N-(oxane-4-yl)-lH-indazol-7-amine; 3-(4-methoxyphenyl)-N-(oxane-4-ylmethyl)-lH-indazol-7-amine; and 2-(7-cyciopentylamino-2-phenyl-lH-indole-5-yl)-ethanol.

[Claim 16]
The composition according to claim 1 for preserving cells, tissues and organs, which comprises as an effective ingredient, a pharmaceutically acceptable salt or isomer of the compound of formula (1).

[Claim 17]
The composition according to claim 1, wherein the cell is animal cell isolated from tissues or organs of human or non-human animals and selected from the group consisting of liver cell, skin cell, mucous membrane cell, Langerhans islet cell, nerve cell, cartilage cell, endothelium cell, epithelial cell, bone cell and muscle cell; or sperm, egg or fertilized egg of livestock or fish.

[Claim 18]
The composition according to claim 1, wherein the organ is selected from the group consisting of skin, cornea, kidney, heart, liver, pancreas, intestine, nerve, lung, placenta, umbilical cord and blood vessel.

[Claim 19]
The composition according to claim 1, wherein the tissue is selected from the group consisting of skin, cornea, kidney, heart, liver, pancreas, intestine, nerve, lung, placenta, umbilical cord and blood vessel.

[Claim 20]
The composition according to claim 1 for preventing injury of organs, isolated cell systems or tissues caused by cold storage, transplant operation or post-transplantation reperfusion.

[Claim 21]
A method of using the composition according to claim 1 for preserving cells, tissues or organs of animals for transplantation.

[Claim 22]
A preparation method of a composition for preserving cells, tissues or organs of animals, comprising a step of mixing a compound of formula (1) according to claim 1 or a pharraaceutically acceptable salt or isomer thereof as an effective ingredient, together with a pharmaceutically acceptable carrier.

[Claim 23]
A method of using the composition according to claim 20 for cultivating or preserving cells, tissues or organs, in manufacturing an artificial organ.

Documents

Application Documents

# Name Date
1 4009-chenp-2010 power of attorney 29-06-2010.pdf 2010-06-29
1 Description(Complete) [02-11-2016(online)].pdf 2016-11-02
2 4009-chenp-2010 pct 29-06-2010.pdf 2010-06-29
2 Form 13 [02-11-2016(online)].pdf 2016-11-02
3 Marked Copy [02-11-2016(online)].pdf 2016-11-02
3 4009-chenp-2010 form-5 29-06-2010.pdf 2010-06-29
4 Other Patent Document [02-11-2016(online)].pdf 2016-11-02
4 4009-chenp-2010 form-3 29-06-2010.pdf 2010-06-29
5 4009-CHENP-2010-Correspondence Pa-201016.pdf 2016-10-21
5 4009-chenp-2010 form-2 29-06-2010.pdf 2010-06-29
6 Form 26 [19-10-2016(online)].pdf 2016-10-19
6 4009-chenp-2010 form-18 29-06-2010.pdf 2010-06-29
7 Other Patent Document [19-10-2016(online)].pdf 2016-10-19
7 4009-chenp-2010 form-1 29-06-2010.pdf 2010-06-29
8 4009-CHENP-2010_EXAMREPORT.pdf 2016-07-02
8 4009-chenp-2010 drawings 29-06-2010.pdf 2010-06-29
9 4009 CHENP 2010-FORM 3.pdf 2015-07-27
9 4009-chenp-2010 description(complete) 29-06-2010.pdf 2010-06-29
10 4009-chenp-2010 correspondence others 29-06-2010.pdf 2010-06-29
10 Petition for Form 3.pdf 2015-07-27
11 4009-chenp-2010 claims 29-06-2010.pdf 2010-06-29
11 Petition for POR.pdf 2015-07-27
12 4009-chenp-2010 abstract 29-06-2010.pdf 2010-06-29
12 4009-CHENP-2010 AMENDED CLAIMS 23-07-2015.pdf 2015-07-23
13 4009-CHENP-2010 AMENDED PAGES OF SPECIFICATION 23-07-2015.pdf 2015-07-23
13 4009-chenp-2010 form-3 24-12-2010.pdf 2010-12-24
14 4009-chenp-2010 power of attorney 24-12-2010.pdf 2010-12-24
14 4009-CHENP-2010 EXAMINATION REPORT REPLY RECEIVED 23-07-2015.pdf 2015-07-23
15 4009-chenp-2010 correspondence others 24-12-2010.pdf 2010-12-24
15 4009-CHENP-2010 FORM-1 23-07-2015..pdf 2015-07-23
16 4009-CHENP-2010 FORM-1 23-07-2015.pdf 2015-07-23
16 4009-P-2010_Petiton 137 - Verification English translation of PCT_26-02-2015-09-50-04-041.pdf ONLINE 2015-02-26
17 4009-P-2010_Petiton 137 - Verification English translation of PCT_26-02-2015-09-50-04-041.pdf 2015-02-26
17 4009-CHENP-2010 OTHER PATENT DOCUMENT 23-07-2015.pdf 2015-07-23
18 4009-CHENP-2010 OTHER PATENT DOCUMENT 26-02-2015.pdf 2015-02-26
18 4009-CHENP-2010 OTHER PATENT DOCUMENT(1) 23-07-2015.pdf 2015-07-23
19 4009-CHENP-2010 ENGLISH TRANSLATION 26-02-2015.pdf 2015-02-26
19 4009-CHENP-2010 EXAMINATION REPORT REPLY RECEIVED 26-02-2015.pdf 2015-02-26
20 4009-CHENP-2010 ENGLISH TRANSLATION 26-02-2015.pdf 2015-02-26
20 4009-CHENP-2010 EXAMINATION REPORT REPLY RECEIVED 26-02-2015.pdf 2015-02-26
21 4009-CHENP-2010 OTHER PATENT DOCUMENT 26-02-2015.pdf 2015-02-26
21 4009-CHENP-2010 OTHER PATENT DOCUMENT(1) 23-07-2015.pdf 2015-07-23
22 4009-CHENP-2010 OTHER PATENT DOCUMENT 23-07-2015.pdf 2015-07-23
22 4009-P-2010_Petiton 137 - Verification English translation of PCT_26-02-2015-09-50-04-041.pdf 2015-02-26
23 4009-CHENP-2010 FORM-1 23-07-2015.pdf 2015-07-23
23 4009-P-2010_Petiton 137 - Verification English translation of PCT_26-02-2015-09-50-04-041.pdf ONLINE 2015-02-26
24 4009-CHENP-2010 FORM-1 23-07-2015..pdf 2015-07-23
24 4009-chenp-2010 correspondence others 24-12-2010.pdf 2010-12-24
25 4009-chenp-2010 power of attorney 24-12-2010.pdf 2010-12-24
25 4009-CHENP-2010 EXAMINATION REPORT REPLY RECEIVED 23-07-2015.pdf 2015-07-23
26 4009-CHENP-2010 AMENDED PAGES OF SPECIFICATION 23-07-2015.pdf 2015-07-23
26 4009-chenp-2010 form-3 24-12-2010.pdf 2010-12-24
27 4009-chenp-2010 abstract 29-06-2010.pdf 2010-06-29
27 4009-CHENP-2010 AMENDED CLAIMS 23-07-2015.pdf 2015-07-23
28 4009-chenp-2010 claims 29-06-2010.pdf 2010-06-29
28 Petition for POR.pdf 2015-07-27
29 4009-chenp-2010 correspondence others 29-06-2010.pdf 2010-06-29
29 Petition for Form 3.pdf 2015-07-27
30 4009 CHENP 2010-FORM 3.pdf 2015-07-27
30 4009-chenp-2010 description(complete) 29-06-2010.pdf 2010-06-29
31 4009-CHENP-2010_EXAMREPORT.pdf 2016-07-02
31 4009-chenp-2010 drawings 29-06-2010.pdf 2010-06-29
32 Other Patent Document [19-10-2016(online)].pdf 2016-10-19
32 4009-chenp-2010 form-1 29-06-2010.pdf 2010-06-29
33 Form 26 [19-10-2016(online)].pdf 2016-10-19
33 4009-chenp-2010 form-18 29-06-2010.pdf 2010-06-29
34 4009-CHENP-2010-Correspondence Pa-201016.pdf 2016-10-21
34 4009-chenp-2010 form-2 29-06-2010.pdf 2010-06-29
35 Other Patent Document [02-11-2016(online)].pdf 2016-11-02
35 4009-chenp-2010 form-3 29-06-2010.pdf 2010-06-29
36 Marked Copy [02-11-2016(online)].pdf 2016-11-02
36 4009-chenp-2010 form-5 29-06-2010.pdf 2010-06-29
37 4009-chenp-2010 pct 29-06-2010.pdf 2010-06-29
37 Form 13 [02-11-2016(online)].pdf 2016-11-02
38 4009-chenp-2010 power of attorney 29-06-2010.pdf 2010-06-29
38 Description(Complete) [02-11-2016(online)].pdf 2016-11-02